Sherlock Biosciences, a company engineering biology to bring next-generation diagnostics to the point of need, today announced the acquisition of Sense Biodetection (Sense), a global molecular diagnostics innovator. The acquisition accelerates Sherlock’s go-to-market strategy by adding Sense’s Veros™ instrument-free rapid molecular test platform and manufacturing capabilities, enabling the vision of highly accurate and affordable diagnostics that can be used anytime, anywhere. Sense is headquartered in Oxford, UK with facilities in Cambridge UK and Milford, MA.
Read the full article: Sherlock Biosciences Acquires Sense Biodetection Advancing CRISPR-Based Diagnostics for Consumers //
Source: https://www.prnewswire.com/news-releases/sherlock-biosciences-acquires-sense-biodetection-advancing-crispr-based-diagnostics-for-consumers-301735616.html